POZ Community Forums

Meds, Mind, Body & Benefits => Research News & Studies => Topic started by: John2038 on August 31, 2011, 06:18:50 pm

Title: New clinical trial: Vacc-4x in combination with Revlimid (Lenalidomide)
Post by: John2038 on August 31, 2011, 06:18:50 pm

The study will determine:

    1. The ability of Vacc-4x to improve immune function in patients that fail to regain a healthy immune defense despite that their viral load is well controlled on conventional HIV-medicines (antiretroviral therapy - ART).

    2. The effect of Revlimid® on Vacc-4x’s ability to improve immune function. Revlimid® is a leading drug for treatment of multiple myeloma and anemia due to myelodysplastic syndrome associated with a deletion in the long arm of the fifth chromosome.

http://www.bionorpharma.com/New+clinical+trial.b7C_wljQ5i.ips

Title: Re: New clinical trial: Vacc-4x in combination with Revlimid (Lenalidomide)
Post by: John2038 on September 01, 2011, 04:02:24 pm

GeoVax $3.6 Million Award Increased to $4.4 Million by U.S. Government
Aggregate Total Award of $20.4 Million for Clinical Development of HIV/AIDS Vaccine

http://www.marketwatch.com/story/geovax-36-million-award-increased-to-44-million-by-us-government-2011-09-01?reflink=MW_news_stmp